<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250611066184N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-05</date_registration>
      <primary_sponsor>Fasa University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of family-centered empowerment on the quality of life and self-efficacy in cancer patients undergoing chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of family-centered empowerment on the quality of life and self-efficacy in cancer patients undergoing chemotherapy in Shariati Fasa Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84321</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Individuals who are willing and meet the entry requirements for the study are divided into two groups: intervention and control based on the random selection software. The randomization method of individuals into two groups is carried out using the Balanced Block Randomization method in the Random Allocation software in a one-to-one ratio.</study_design>
      <phase>3</phase>
      <hc_freetext>in cancer patients undergoing chemotherapy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Before the intervention, the demographic characteristics checklist, quality of life questionnaire, and self-efficacy questionnaire are completed by the intervention group. And a pre-test is taken from the sample units. For the test group, the family-centered empowerment program is based on the steps of the empowerment model and according to the designed educational program. The first step (perception of threat) sessions will be held in groups of 10 people, consisting of 5 patients and 5 family members (one member of the main family caregiver), in the form of discussion and exchange of opinions and questions and answers by the researcher in one of the hospital meeting rooms using educational aids such as whiteboards, projectors, and PowerPoint. After selecting the first 5 patients, the first step empowerment sessions will be held with a family member of the patient, and the subsequent sessions for the subsequent steps will be held individually (one patient and one family member). The interval between sessions will be between 5 and 7 days, depending on the patient and the family caregiver. The patient will participate in these sessions with the family caregiver. The researcher will have the role of educational, supportive, and guiding participation. The intervention stages are as follows:. The steps of the family-centered empowerment model will be carried out in four main steps: 1- Understanding the threat, 2- Promoting self-efficacy/problem solving, 3- Promoting self-confidence and self-esteem through educational participation, and 4- Evaluation: 1. Step 1, Understanding the threat: The first step in the family-centered empowerment model is to increase perceived severity and sensitivity. The purpose of perceived severity (awareness and knowledge of the individual about the disease) is for the individual to understand the seriousness of the disease by recognizing the risks or complications of the disease and to feel threatened by it. In order to sensitize and increase the level of information of patients and their families, group sessions will be held on the nature of the disease, symptoms, complications, prognosis of the disease, diet, treatment regimen, physical activities, and laboratory tests during two sessions (each session 40 to 60 minutes) with educational aids. At the end of the training sessions, questions and answers will be held to ensure understanding of the material. Both the patient and the family caregiver will participate in the discussions and their problems will be identified, discussed and prioritized. 2. The second step, self-efficacy: Problem solving or problem solving will be implemented in a group method. For this purpose, problem solving sessions (two 40-60 minute sessions) will be held for a group of patients and their families. In these sessions, patients and families will practically face problems and the problem-solving process. In these two sessions, the skills necessary for better disease control will be explained and practiced. Then, patients and families will be asked to practice this skill. For example, one of the problems faced by patients undergoing chemotherapy is nausea and vomiting, and the type of drug that controls this condition and the dosage amount will be demonstrated in class. Also, with regard to the condition of hair loss, how to use a wig will be taught and practiced. 3. Step Three, Self-Belief and Increased Self-Confidence: In this step, the patient will be asked to teach the family the material discussed in the previous sessions during a session and to do so with the researcher's help and guidance if needed. The goal of this step is to increase the patients' self-confidence due to observing their ability to provide information to family members and support the family. 4. Step Four, Evaluation: Evaluation consists of 2 steps. 1- Process evaluation 2- Final evaluation 5. Process evaluation will be carried out during the empowerment sessions in such a way that the educational materials of the previous sessions will be evaluated in the form of questions and answers in the next session. The final evaluation will be carried out immediately and two months after the intervention, quality of life and self-efficacy questionnaires will be completed by both intervention groups. And a post-test will be taken again. During this period, the researcher will follow up with the patient and the family caregiver via telephone call. Follow-up and telephone call will be made every 5 days for 5 to 10 minutes to answer their questions. Intervention 2: Control group: Initially, the demographic characteristics checklist, quality of life questionnaire, and efficacy questionnaire are completed by the control group and a pre-test is administered to them. The control group receives training in the form of lectures and face-to-face according to the routine of the inpatient ward. Considering that the training received by patients is during hospitalization and at the time of discharge from the hospital, the quality of life questionnaire and self-efficacy questionnaire are completed again at the time of discharge, and a post-test is also administered. In the following two months, the quality of life and self-efficacy questionnaires are completed and the post-test is administered again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data is shareable after individuals are de-identified.

When:
Access begins 4 months after results are published.

To whom:
Researchers working in academic institutions

Conditions:
To write meta-analysis studies

Where to obtain:
Dr. Azam Zare - Fasa University of Medical Sciences

How to obtain:
Submit a written request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azam Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ibn- sina square</address>
        <city>Fasa</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۴۶۱۶-۸۶۶۸۸</zip>
        <telephone>+98 71 5335 0994</telephone>
        <email>a.zare2002@gmail.com</email>
        <affiliation>Fasa University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azam Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ibn-sina square</address>
        <city>fasa</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۴۶۱۶-۸۶۶۸۸</zip>
        <telephone>+98 71 5335 0994</telephone>
        <email>a.zare2002@gmail.com</email>
        <affiliation>Fasa University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At least two months have passed since the diagnosis of cancer
, having a caregiver or active family member
not suffering from serious and debilitating complications of cancer
undergoing chemotherapy
able to speak and communicate
able to read and write
not suffering from another chronic disease
adults aged 30 to 60 years
willing to participate in the study
, interested and able to learn the material</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Absence of more than one session in training sessions
unwillingness to continue cooperation in the present study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z51.11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for antineoplastic chemotherapy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Before the intervention, the demographic characteristics checklist, quality of life questionnaire, and self-efficacy questionnaire are completed by the intervention group. And a pre-test is taken from the sample units. For the test group, the family-centered empowerment program is based on the steps of the empowerment model and according to the designed educational program. The first step (perception of threat) sessions will be held in groups of 10 people, consisting of 5 patients and 5 family members (one member of the main family caregiver), in the form of discussion and exchange of opinions and questions and answers by the researcher in one of the hospital meeting rooms using educational aids such as whiteboards, projectors, and PowerPoint. After selecting the first 5 patients, the first step empowerment sessions will be held with a family member of the patient, and the subsequent sessions for the subsequent steps will be held individually (one patient and one family member). The interval between sessions will be between 5 and 7 days, depending on the patient and the family caregiver. The patient will participate in these sessions with the family caregiver. The researcher will have the role of educational, supportive, and guiding participation. The intervention stages are as follows:. The steps of the family-centered empowerment model will be carried out in four main steps: 1- Understanding the threat, 2- Promoting self-efficacy/problem solving, 3- Promoting self-confidence and self-esteem through educational participation, and 4- Evaluation: 1. Step 1, Understanding the threat: The first step in the family-centered empowerment model is to increase perceived severity and sensitivity. The purpose of perceived severity (awareness and knowledge of the individual about the disease) is for the individual to understand the seriousness of the disease by recognizing the risks or complications of the disease and to feel threatened by it. In order to sensitize and increase the level of information of patients and their families, group sessions will be held on the nature of the disease, symptoms, complications, prognosis of the disease, diet, treatment regimen, physical activities, and laboratory tests during two sessions (each session 40 to 60 minutes) with educational aids. At the end of the training sessions, questions and answers will be held to ensure understanding of the material. Both the patient and the family caregiver will participate in the discussions and their problems will be identified, discussed and prioritized. 2. The second step, self-efficacy: Problem solving or problem solving will be implemented in a group method. For this purpose, problem solving sessions (two 40-60 minute sessions) will be held for a group of patients and their families. In these sessions, patients and families will practically face problems and the problem-solving process. In these two sessions, the skills necessary for better disease control will be explained and practiced. Then, patients and families will be asked to practice this skill. For example, one of the problems faced by patients undergoing chemotherapy is nausea and vomiting, and the type of drug that controls this condition and the dosage amount will be demonstrated in class. Also, with regard to the condition of hair loss, how to use a wig will be taught and practiced. 3. Step Three, Self-Belief and Increased Self-Confidence: In this step, the patient will be asked to teach the family the material discussed in the previous sessions during a session and to do so with the researcher's help and guidance if needed. The goal of this step is to increase the patients' self-confidence due to observing their ability to provide information to family members and support the family. 4. Step Four, Evaluation: Evaluation consists of 2 steps. 1- Process evaluation 2- Final evaluation 5. Process evaluation will be carried out during the empowerment sessions in such a way that the educational materials of the previous sessions will be evaluated in the form of questions and answers in the next session. The final evaluation will be carried out immediately and two months after the intervention, quality of life and self-efficacy questionnaires will be completed by both intervention groups. And a post-test will be taken again. During this period, the researcher will follow up with the patient and the family caregiver via telephone call. Follow-up and telephone call will be made every 5 days for 5 to 10 minutes to answer their questions.</i_keyword>
      <i_keyword>Control group: Initially, the demographic characteristics checklist, quality of life questionnaire, and efficacy questionnaire are completed by the control group and a pre-test is administered to them. The control group receives training in the form of lectures and face-to-face according to the routine of the inpatient ward. Considering that the training received by patients is during hospitalization and at the time of discharge from the hospital, the quality of life questionnaire and self-efficacy questionnaire are completed again at the time of discharge, and a post-test is also administered. In the following two months, the quality of life and self-efficacy questionnaires are completed and the post-test is administered again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Quality of life. Timepoint: before, after and 2 month after. Method of measurement: To assess quality of life, a specific questionnaire for measuring quality of life in cancer patients, developed by Arneson in 1987, is used. This questionnaire was standardized by Montazeri and colleagues in Iran.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Self efficacy. Timepoint: before, after and two month after. Method of measurement: The Self-Care Self-Efficacy Questionnaire was first designed by Lu in 1996 for cancer patients and was translated into a Persian version and used by Azizi.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Fasa University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-26</approval_date>
        <contact_name>Ethics committee of Fasa University of Medical Sciences</contact_name>
        <contact_address>Abn Sina Squre Fasa Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
